Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Vascular Surgery
Published in: Annals of Vascular Surgery 3/2006

01-05-2006 | Clinical Research

The Elevated Level of Circulating Matrix Metalloproteinase-9 in Patients with Abdominal Aortic Aneurysms Decreased to Levels Equal to Those of Healthy Controls after an Aortic Repair

Authors: Tetsuo Watanabe, MD, PhD, Akira Sato, MD, PhD, Takashi Sawai, MD, PhD, Miwa Uzuki, MD, PhD, Hitoshi Goto, MD, PhD, Hiroshi Yamashita, MD, PhD, Daijirou Akamatsu, MD, PhD, Hiroko Sato, MD, PhD, Takuya Shimizu, MD, Noriyuki Miyama, MD, Yoshiyuki Nakano, MD, Susumu Satomi, MD, PhD

Published in: Annals of Vascular Surgery | Issue 3/2006

Login to get access

Abstract

Matrix metalloproteinase-9 (MMP-9) is abundantly expressed in abdominal aortic aneurysms (AAAs), and it is considered to play a pivotal role in aneurysmal formation. Elevated circulating concentrations of MMP-9 have been reported in patients with AAA, but the influence of an operation on circulating MMP-9 is unclear. Therefore, to clarify the influence of an operation on circulating MMP-9 levels and to determine the role of MMP-9 in the progression of AAA, we measured serum MMP-9 levels in patients before and after AAA repair. Blood samples were obtained from 53 patients with AAA; 22 patients underwent AAA operations, including 17 patients with arterial occlusive disease (AOD), and nine normal control subjects. Serum MMP-9 levels were determined by an enzyme-linked immunosorbent assay. The serum MMP-9 concentration was significantly higher in AAA patients (622.0 ± 400.2 ng/mL) than in either AOD patients (284.3 ± 151.4 ng/mL) or healthy controls (280.8 ± 165.5 ng/mL) (p < 0.001). The mean serum MMP-9 levels in patients undergoing surgery for AAA (268.1 ± 215.9 ng/mL) was significantly lower than that in AAA patients (p < 0.01). Among the 10 patients whose sera were obtained preoperatively and postoperatively, the serum MMP-9 concentration fell significantly after the patients underwent the operation (p = 0.004). No significant difference was identified in serum MMP-9 concentrations among AOD patients, controls, and postoperative patients. These studies suggest that MMP-9 plays a pivotal role in aneurysm formation, and the circulating MMP-9 level is thus considered to reflect the biological behavior of the aneurysm.
Literature
1.
Ailawadi G, Eliason JL, Upchurch GR Jr. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg 2003;38:584–588PubMedCrossRef
2.
Rizzo RJ, McCarthy WJ, Dixit SN, et al. Collagen types and matrix protein content in human abdominal aortic aneurysms. J Vasc Surg 1989;10:365–373PubMedCrossRef
3.
Baxter BT, Halloran BG. Matrix protein metabolism in abdominal aortic aneurysms In: Yao JST, Pearce WH eds. Aneurysms. New Findings and Treatments. Nortwalk: Appleton & Lange, 1994, pp 25–34
4.
Carrell TWG, Burnand KG, Wells GMA, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2001;105:477–482CrossRef
5.
Newman KM, Malon AM, Shin RD, et al. Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res 1994;30:265–276PubMedCrossRef
6.
Knox JB, Sukhova GK, Whittemore AD, et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997;95:205–212PubMed
7.
McMillan WD, Patterson BK, Keen RR, et al. In situ localization and quantification of seventy-two-killodalton type IV collagenase in aneurysmal, occlusive and normal aorta. J Vasc Surg 1995;22:295–305PubMedCrossRef
8.
Freestone T, Turner RJ, Coady A, et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Atheroscler Thromb Vasc Biol 1995;15:1145–1151
9.
Sakalihansan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005;365:1577–1589CrossRef
10.
Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995;96:318–326PubMedCrossRef
11.
Sakalihasan N, Delvenne P, Nusgens BV, et al. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 1996;24:127–133PubMedCrossRef
12.
Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625–632PubMed
13.
Watanabe T, Sawai T, Sato A, et al. The role of matrix metalloproteinases in progression of abdominal aortic aneurysm. J Jpn Coll Angiol 2000;40:505–510
14.
Watanabe T, Sawai T, Sato A, et al. Mapping analysis of the distribution of MMP-2 and MMP-9 in the wall of abdominal aortic aneurysms and correlation with the disruption of elastic fibers. Jpn J Vasc Surg 2000;9:539–544
15.
Tilson MD, Newman KM. Proteolytic mechanisms in the pathogenesis of aortic aneurysms. In: Yao JST, Pearce WH eds. Aneurysms. New Findings and Treatments. Norwalk: Appleton & Lange, 1994, pp 3–10
16.
Hovsepian DM, Ziporin SJ, Sakurai MK, et al. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000;11:1345–1352PubMedCrossRef
17.
McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999;29:122–129PubMedCrossRef
18.
Lindholt JS, Vammen S, Fasting H, et al. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg 2000;20:281–285PubMedCrossRef
19.
Seki M, Uzuki M, Ohmoto H, et al. Matrix metalloproteinase (MMP-9) in patients with rheumatoid arthritis. Ryumachi 1995;35:792–801PubMed
20.
Hibbs MS. Expression of 92kDa phagocyte gelatinase by inflammatory and connective tissue cells. Matrix 1992;(Suppl. 1):51–57
Metadata
Title
The Elevated Level of Circulating Matrix Metalloproteinase-9 in Patients with Abdominal Aortic Aneurysms Decreased to Levels Equal to Those of Healthy Controls after an Aortic Repair
Authors
Tetsuo Watanabe, MD, PhD
Akira Sato, MD, PhD
Takashi Sawai, MD, PhD
Miwa Uzuki, MD, PhD
Hitoshi Goto, MD, PhD
Hiroshi Yamashita, MD, PhD
Daijirou Akamatsu, MD, PhD
Hiroko Sato, MD, PhD
Takuya Shimizu, MD
Noriyuki Miyama, MD
Yoshiyuki Nakano, MD
Susumu Satomi, MD, PhD
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Annals of Vascular Surgery / Issue 3/2006
Print ISSN: 0890-5096
Electronic ISSN: 1615-5947
DOI
https://doi.org/10.1007/s10016-006-9038-7

Other articles of this Issue 3/2006

Annals of Vascular Surgery 3/2006 Go to the issue

Report

Intravenous Uterine Leiomyomatosis with Right Heart Extension: Successful Two-Stage Surgical Removal

Developments in Endovascular Surgery

Aortic Neck Dilation after Endovascular Abdominal Aortic Aneurysm Repair: Should Oversizing Be Blamed?

Clinical Research

A Comparison between Cryosurgery and Conventional Stripping in Varicose Vein Surgery: Perioperative Features and Complications

Basic Science Research

Venous Ulcer Fibroblasts Respond to Basic Fibroblast Growth Factor at the Cell Cycle Protein Level

Developments in Endovascular Surgery

Endovascular Repair of Thoracic Aortic Lesions Using Infrarenal Devices: Lessons Learned and Continued Applications

OriginalPaper

Influence of Indomethacin in the Rat Aneurysm Model